|
(NVS) Novartis Gets Setback From FDA Panel
By:
Stock Blog Hub
Posted on June 22, 2011 at 21:03 PM EDT
Novartis (NVS) received a setback recently when an advisory panel to the US Food and Drug Administration (FDA) recommended against approving its pipeline candidate ACZ885 for the proposed indication. Novartis was seeking approval to expand the use of ACZ885 for the treatment of patients suffering from severe gouty arthritis, commonly known as gout, who failed [...] (NVS) Novartis Gets Setback From FDA Panel
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes. Markets are closed on certain holidays. Stock Market Holiday List By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. Press Release Service provided by PRConnect. Stock quotes supplied by Telekurs USA Postage Rates Bots go here |
